Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondar
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement
Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript
02:26pm, Thursday, 06'th Nov 2025
Altimmune, Inc. ( ALT ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Vipin Garg - President, CEO & Director Linda Richardson - Chief Commercial Officer Gregory Weaver - Chie
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
07:00am, Thursday, 06'th Nov 2025
48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened w
Altimmune to Participate in Two Upcoming Investor Conferences
07:30am, Wednesday, 05'th Nov 2025
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometa
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
07:30am, Monday, 03'rd Nov 2025
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
07:30am, Thursday, 30'th Oct 2025
GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometa
Analyzing ALT5 Sigma (NASDAQ:ALTS) and Euronet Worldwide (NASDAQ:EEFT)
03:06am, Sunday, 26'th Oct 2025
ALT5 Sigma (NASDAQ: ALTS - Get Free Report) and Euronet Worldwide (NASDAQ: EEFT - Get Free Report) are both finance companies, but which is the superior business? We will compare the two companies bas
Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmun
ALT5 Sigma Treasury Strategy Supported by World Liberty Financial's International Expansion and $WFLI Token Burn
08:00am, Tuesday, 14'th Oct 2025
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the "Company," "our" or "ALT5") (NASDAQ: ALTS) (FRA:5AR1), the $WLFI digital asset treasury company, today noted continued World Liberty Financial (
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you are a long-term
ALT5 Sigma Issues Letter to Stockholders
04:05pm, Wednesday, 08'th Oct 2025
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the "Company," "our" or "ALT5") (NASDAQ: ALTS) (FRA:5AR1), the $WLFI digital asset treasury company, today issued a letter to its stockholders: Dear
ALT5 Sigma and World Liberty Financial to Present at A.G.P.'s Digital Assets & Technology Showcase
07:31pm, Tuesday, 07'th Oct 2025
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the "Company," "our" or "ALT5") (NASDAQ: ALTS) (FRA:5AR1), the $WLFI digital asset treasury company, today announced that it will participate in A.G
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
07:24am, Tuesday, 07'th Oct 2025
LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "th
Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT
04:49pm, Monday, 06'th Oct 2025
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
